Molecular Endocrinology, Vol 5, 1880-1886, Copyright © 1991 by Endocrine Society

ARTICLES

Single amino acid substitutions in recombinant bovine prolactin that markedly reduce its mitogenic activity in Nb2 cell cultures

DN Luck, M Huyer, PW Gout, CT Beer and M Smith
Department of Biochemistry, Faculty of Medicine, University of British Columbia, Vancouver, Canada.

Three amino acid residues of bovine PRL (bPRL) have been examined for their roles in the mitogenic activity of the hormone in Nb2 lymphoma cell cultures. The residues of interest, R21, R177, and K187, are conserved in eight pituitary PRLs, but not in the related, nonlactogenic bGH. Using site-specific mutagenesis, a number of recombinant methionyl bPRL variants have been prepared, each of which contained a single amino acid substitution of one of the three residues; a variety of amino acids was used for substitution. Twelve exchanges of R177 (to A, L, N, K, D, E, Y, G, S, Q, H, and F) all led to marked decreases in mitogenic activity. Even the conservative change, R177K, led to a decrease in mitogenic activity of about 90%; all the other R177 substitutions led to even more marked decreases; there was essentially complete loss of activity when the positively charged R177 was replaced by the negatively charged aspartate. Exchanges of R21 (to A, L, N, and K) were less dramatic, with the greatest decrease (79%) occurring in the case of R21A. Exchanges of K187 (to A, L, N, and R) had a relatively minor effect on the mitogenic activity of the hormone. Residues R21 and R177 in bPRL are located in putative helices 1 and 4, respectively; in the three-dimensional structure of the hormone these residues are predicted to be quite closely apposed. The results suggest that R177 and, to a lesser degree, R21 have important roles in the mitogenic activity of bPRL.

This article has been cited by other articles:

				L. A. Svensson, K. Bondensgaard, L. Norskov-Lauritsen, L. Christensen, P. Becker, M. D. Andersen, M. J. Maltesen, K. D. Rand, and J. Breinholt Crystal Structure of a Prolactin Receptor Antagonist Bound to the Extracellular Domain of the Prolactin Receptor J. Biol. Chem., July 4, 2008; 283(27): 19085 - 19094. [Abstract] [Full Text] [PDF]

				W. Y. Chen, P. Ramamoorthy, N.-y. Chen, R. Sticca, and T. E. Wagner A Human Prolactin Antagonist, hPRL-G129R, Inhibits Breast Cancer Cell Proliferation through Induction of Apoptosis Clin. Cancer Res., November 1, 1999; 5(11): 3583 - 3593. [Abstract] [Full Text] [PDF]

				T.-J. Chen, C. B. Kuo, K. F. Tsai, J.-W. Liu, D.-Y. Chen, and A. M. Walker Development of Recombinant Human Prolactin Receptor Antagonists by Molecular Mimicry of the Phosphorylated Hormone Endocrinology, February 1, 1998; 139(2): 609 - 616. [Abstract] [Full Text] [PDF]

				V. Goffin, S. Kinet, F. Ferrag, N. Binart, J. A. Martial, and P. A. Kelly Antagonistic Properties of Human Prolactin Analogs That Show Paradoxical Agonistic Activity in the Nb2 Bioassay J. Biol. Chem., July 12, 1996; 271(28): 16573 - 16579. [Abstract] [Full Text] [PDF]

				S. Kinet, V. Goffin, V. Mainfroid, and J. A. Martial Characterization of Lactogen Receptor-binding Site 1of Human Prolactin J. Biol. Chem., June 14, 1996; 271(24): 14353 - 14360. [Abstract] [Full Text] [PDF]

				Y.-F. Wang, J.-W. Liu, M. Mamidi, and A. M. Walker Identification of the Major Site of Rat Prolactin Phosphorylation as Serine 177 J. Biol. Chem., February 2, 1996; 271(5): 2462 - 2469. [Abstract] [Full Text] [PDF]